A phase II study of Carboplatin AUC 10 guided by PET defined metabolic response in metastatic seminoma

Jonathan Shamash1,3, Rizwan Syed2, Shah - Jalal Sarker3, Naveed Sarwar4, Anand Sharma5, Katherine Mutsvangwa1, Carike Coetzee3, Peter Wilson1, Gordon J. Rustin5

1. Department of Medical Oncology, Barts Health NHS Trust, London, United Kingdom
2. Department of Nuclear Medicine, University College Hospitals NHS Foundation Trust, London, United Kingdom
3. Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
4. Department of Medical Oncology, Imperial College Healthcare NHS Trust, London, United Kingdom
5. Department of Oncology, Hillingdon Hospitals NHS Foundation Trust, London, United Kingdom

Corresponding author:
Dr Jonathan Shamash, MD FRCP
Consultant Medical Oncologist
Centre for Experimental Cancer Medicine
Barts Cancer Institute
Queen Mary University of London
London EC1M 6BQ
Tel: 020 3465 7108
Fax: 020 7882 8409
E-mail: Jonathan.Shamash@bartshealth.nhs.uk

Keywords: Carboplatin monotherapy, metastatic seminoma
Abstract
Introduction
Carboplatin monotherapy for metastatic seminoma at a dose of AUC 10 has shown promising activity. Three or 4 cycles have been given with most haematological side effects seen with the 4th cycle. An early response might allow de-escalation of therapy.

Methods
Forty-eight patients with metastatic seminoma (IGCCCG good prognosis) were recruited. PET scanning was performed prior to and after 1 cycle of carboplatin. Those with a Deauville score of 3 or less were given a total of 3 cycles of carboplatin, the rest received 4.

Results
PET scanning allowed 44% to receive 3 cycles of carboplatin. With a median follow up of 31.2 months 95.6% (95% CI: 83.5%-98.9%) were progression free. The overall survival at 2-years was 100%. Lower stage (2A and 2B) disease was significantly \( P=0.001 \) associated with the better metabolic response but the association was not strong (Correlation coefficient=-0.48). Over a third of the blood products given were used to support the 4th cycle. The regimen was well tolerated with a low incidence of grade 3 neutropenic sepsis or nausea and vomiting (<3% cycles).

Conclusion
Carboplatin AUC 10 monotherapy is effective with low toxicity. Early changes during PET scanning may allow de-escalation of therapy in high volume disease – comparison against combination therapy is warranted.

Clinicaltrials.gov identifier: NCT02272816
EudraCT number: 2009-009882-33.
Introduction

Metastatic seminoma is very responsive to current therapies. It is both very chemo-sensitive and radiosensitive. Seminomas appear more sensitive to both these modalities than non-seminomas. Attempts to reduce toxicity of combination chemotherapy in seminoma using carboplatin was first attempted in the early 1990s. Studies comparing carboplatin 400mg/m$^2$,\textsuperscript{1} or AUC 5,\textsuperscript{2} to combination cisplatin and etoposide based chemotherapy with either ifosfamide or bleomycin yielded similar findings namely a lower progression-free survival (PFS) with carboplatin although overall survival in the two studies was not significantly worse. A meta-analysis suggested however that there might be a reduction in overall survival as well.\textsuperscript{1} Inadequate dosing of carboplatin might be the reason for this.

Long-term studies looking at the effect of combination cisplatin-based chemotherapy in germ cell tumours have highlighted the significant long-term side effects – in particular cardiovascular, neurological and second malignancies as well as the predictable but significant acute side effects. This, despite the excellent overall outcomes using cisplatin and etoposide with or without a third drug, has made the further evaluation of carboplatin monotherapy attractive. In addition, qualitative assessments suggest better physical and psychological functioning with reduced time off work during single agent carboplatin for metastatic seminoma.\textsuperscript{3}

We previously conducted a pilot study of carboplatin AUC 10 in metastatic seminoma.\textsuperscript{4} In this study patients were re-scanned at 21 days, those who were in complete remission received a further 2 cycles and the rest received a further 3. The response rate and overall survival was impressive but it was clear that a lot of the transfusion requirements were concentrated in the 4th cycle. It was also evident that only patients with 2A disease were attaining a complete response (CR) after 1 cycle. An initial overview of outcome of an unselected group of patients treated by our group showed reassuring progression-free and overall survival.\textsuperscript{5}

We postulated that this was due to the volume of disease at the start and that positron emission tomography – computerized tomography (PET - CT) scanning would allow us to identify patients who had responded well but still had residual masses after 21 days. It was therefore proposed to prospectively evaluate PET scanning in metastatic seminoma. As there was no data to use to define what constituted a complete metabolic response in this disease – we chose to adopt the Deauville criteria used to assess response in lymphoma.\textsuperscript{6} We therefore set up the Car-PET study with the primary endpoint of progression-free survival rate at 2 years and the secondary endpoints of toxicity and metabolic response rate.
Material and Methods

Study population

Patients with metastatic chemotherapy and radiotherapy naïve seminoma who had International Germ Cell Cancer Collaborative Group (IGCCCG) good prognosis disease (i.e. no non-pulmonary visceral metastases) were recruited into the study at two centres, St Bartholomew’s Hospital and Mount Vernon Hospital both in London, United Kingdom. Inclusion criteria included creatinine clearance of over 25ml/min (assessed preferably using an ethylenediaminetetraacetic acid (EDTA) clearance), performance status 0-3, male sex and age range between 18 and 75 years. Exclusion criteria included any patient with non-pulmonary visceral metastases, previous chemotherapy or retroperitoneal radiotherapy and raised alpha-fetoprotein (AFP). Patients were required to give written informed consent. The trial had ethical review and is registered on clinicaltrials.gov, identifier NCT02272816, and with https://www.clinicaltrialsregister.eu, EudraCT number 2009-009882-33.

Study design

Patients required a fluoro-deoxyglucose (FDG) PET – CT scan prior to study entry and a formal EDTA clearance to measure glomerular filtration rate (GFR). Carboplatin AUC 10 according to the Calvert formula (10 x (GFR (ml/min) + 25) mg was given in 5% glucose over 1 hour every 21 days. Standard anti-emetics were employed (5HT3 antagonist and dexamethasone prior to therapy followed by two days of oral dexamethasone and metoclopramide). A repeat PET-CT scan was carried out on day 17-21 of the first cycle. The PET - CT scans were centrally reviewed. If the PET - CT scan showed a complete response (Deauville ≤3) the patient would stop after 3 cycles. If the PET – CT showed persistent activity (Deauville >3), then patients went on to have 4 cycles in total, see Figure 1. There was no routine use of growth factors. Filgrastim was given in cases where white cell recovery was delayed or in symptomatic neutropenia only.

Overall response

Overall treatment responses were measured using the same criteria described in our previous phase II study,4 which are consistent with other published reports. Progressive disease (PD) was defined as the development of new sites of disease with rising tumour markers if present. Stable disease was defined as the lack of any new sites of disease and a <90% reduction in tumour markers, 28 days after chemotherapy. Marker-positive partial response (M+ve PR) was defined as a >90% reduction in tumour markers (without normalisation) for ≥28 days, and no new sites of disease. Marker-negative PR (M-ve PR) was defined as a normalisation of tumour markers and no new sites of disease for ≥28 days. For those patients who had normal
tumour markers before chemotherapy, a M-ve PR required a $\geq 50\%$ reduction in the bi-dimensional measurements of the residual masses to be maintained for $\geq 28$ days. CR was defined as a normalisation of tumour markers with a complete resolution of all sites of disease. Postsurgical outcome was defined as outcome after surgery performed to remove all sites of disease, and patients who achieved a radiological CR to chemotherapy alone or had a surgically induced CR were deemed to have no evidence of disease (NED).

**PET-CT assessment**

There are currently no validated metabolic response criteria for PET-CT in seminoma. Hence, we used the Deauville criteria for assessment of response developed for the evaluation of lymphoma.\(^6\) This is shown in table 1. All PET-CT scans were centrally reviewed at University College London Hospitals NHS Foundation Trust.

**Dose reductions and delays**

These are shown in Figure 2. If the bloods were not up to treatment on the planned date a dose delay of 48 hours was permitted according the schedule below. Importantly, dose reductions were only made for platelet counts of $< 20 \times 10^9/l$.

**Statistical analysis**

The primary objective was to gain a preliminary indication on whether carboplatin AUC-10 is worthwhile considering in a phase III study, using the PFS rate as a criterion. A'Hern’s single-stage procedure is used to estimate the number of patients required.\(^7\) The primary outcome was the percentage of patient’s progression-free at 2-years. Therefore, all patients had at least 2-years follow-up (unless they had died or their disease had progressed). Previous studies,\(^1,2\) showed that Carboplatin AUC-10 should not have a 2-year PFS rate of 75% or less, and it would only be worth considering in a phase III study if the true rate were 90% or more. Based on this information A'Hern's single stage design yield a sample size of 45 patients, with 80% power and one-sided test of significance at the 5% level. To allow for a 10% drop-out rate the intention was to recruit up to a maximum of 50 patients if needed.

The primary efficacy endpoint was the PFS rate at 2 years measured from the date of study enrolment to the date of disease progression or death. Patients who did not complete 2-year follow-up for reasons other than death were censored at the last date of follow-up. The PFS rate was determined for the Carboplatin AUC-10, along with a one-sided 95% confidence interval according to the Kaplan-Meier method. Standard techniques of descriptive statistics were used. The association between disease stage and metabolic response was calculated
using Spearman and Kendall’s rank correlation coefficients and tested using Fisher’s exact test.

The analysis of safety included all patients who received at least one cycle of treatment. Safety and tolerability of Carboplatin AUC-10 are determined by an evaluation of changes in laboratory parameters, vital signs, the incidence and severity of Adverse Events and of toxicities according to the Common Terminology Criteria for Adverse Events (CTCAE) classification (version 4.03).

**Results**

Between February 2012 and May 2015, 48 patients were consented and started treatment with carboplatin. One patient was withdrawn from treatment after cycle 1.

Patient demographic and tumour characteristics are shown in table 2. Out of 48 patients, 46 were testicular and 2 were extragonadal. Twenty-seven percent (13) patients had stage 2A disease, 48% (23) had stage 2B disease and 23% (11) had stage 2C disease. The median age was 36 years (24-66). One patient had a mediastinal primary seminoma. Twenty-five percent (12) of patients had a raised Beta-Human Chorionic Gonadotropin (BHCG) and 27% had raised Lactate Dehydrogenase (LDH). Forty-three patients had their GFR calculated from a formal EDTA clearance. The EDTA clearance range was large (68-236ml/min) with a median of 106ml/min. All patients had a PET-CT scan prior to Cycle 2.

Twenty-one had a metabolic CR with the first cycle of treatment and went on to receive a total of 3 cycles. Twenty-six (excluding the patient who dropped out) had a PR and went on to receive a total of 4 cycles.

Eight of the 21 metabolic CRs had at least a radiological PR prior to cycle 2 and the overall results are shown in Table 3. Of note, the number of patients with 2A, 2B and 2C disease having 3 or 4 cycles were respectively (9, 4); (12, 10) and (0, 11). Fisher’s exact test showed a significant association between lower stage disease and lower cycles of treatment received ($P=0.001$). Similarly, Fisher’s exact test between disease stage and metabolic response at the end of cycle 1 showed that there was a significant association between lower stage disease and better metabolic response ($P=0.001$), see table 3, however, the association was not strong (Spearman rank correlation rho=-0.48, $P<0.001$; Kendall’s tau-b=-0.46, $P=0.001$).

In the trial, 95.6% (46/48) (1-sided 95% CI: ≤ 98.6% and 2-sided 95% CI: 83.5%-98.9%) patients were progression-free at 2 years. 2 patients progressed – at 14 and 24 months
respectively - both patients had had a partial metabolic response to carboplatin and a radiological partial response overall. One patient aged 39 years with stage 2B disease had previous traumatic spinal damage and poor bladder emptying requiring intermittent self-catheterization – he had a large bladder stone which was a source of infection. He received 4 cycles of carboplatin relapsed 24 months later with an isolated dural metastasis presenting with headaches – this radiologically appeared to be a meningioma but when excised was found to be seminoma. He had no other sites of progression – he received bleomycin, etoposide and platinum (BEP) chemotherapy and is currently progression-free. The other patient aged 59 years had stage 2C disease, he received 4 cycles of carboplatin. He relapsed 14 months later – went on to have further treatment initially with BEP which failed and then high dose chemotherapy and stem cell transplant and was alive with disease at the time of data lock.

There were no deaths at the time of data lock. The patient withdrawn from the treatment after cycle 1 (partial metabolic response) had developed severe Raynaud’s phenomenon and gastro-intestinal bleeding due to gastric antrum vascular ectasia (GAVE). He had stage 2A disease and completed treatment with para-aortic irradiation and is progression free.

The number of patients requiring a dose reduction was 9. This was because of low platelets (< 20 x 10⁹/l) in cycle 3 or 4. The median cycle length was 22 days between cycle 1 and 2 (range: 21-28) - 45% received treatment on time, 21% were delayed by up to 2 days, 28% by 2-5 days and 6.4% by more than 5 days. The median cycle length between cycle 2 and 3 was 23 days (range: 21-27) - 40% received the treatment on time, 30% were delayed by up to 2 days, 28% by 3-5 days, and 2% by more than 5 days. The median cycle length between cycle 3 and 4 was 23 days (range: 21-31) - 32% received the treatment on time, 36% were delayed by up to 2 days, 24% by 3-5 days and 8% by more than 5 days.

In the first 3 cycles, 8 out of 47 patients required blood products: 6 required red cells alone and 2 required red cells and platelets. Of the 26 patients requiring 4 cycles, 5 required blood products: red cells in 4 and platelets alone in 1.

Grade 3 and 4 toxicities are shown in table 4. Non-haematological toxicity was very low. The number of grade 3 febrile neutropenic episodes was in 2.4% of cycles. This was despite the absence of prophylactic antibiotics or routine use of growth factors. The number of cycles complicated by significant nausea/vomiting (grade 3) was 3%.
The neurological toxicity was low – there was no grade 2 or higher neuropathy. There were 6 occurrences of grade 1 sensory neuropathy. The number of cycles complicated by tinnitus was 7% by grade 1 and 2% by grade 2. There was only 1 occurrence of grade 3 ototoxicity (tinnitus), 3 occurrences of grade 2 tinnitus and 12 occurrences of grade 1 tinnitus. Although 13 patients reported tinnitus it had resolved in 11 by cycle 4. In the single patient who reported grade 3 tinnitus – it had reduced to grade 1 by cycle 4.

Haematological toxicity was predominantly anaemia. A total of 27 units of blood were given to 8 patients, 4 received blood on the 4th cycle. Platelet transfusions were required by 4 patients.

Overall, patients with EDTA>120ml/min experienced less than half of the toxicities than those with EDTA≤120ml/min. For example, grade 3 anaemia, neutropenia and thrombocytopenia occurrences were 5.4%, 15.5% and 15.5% of cycles respectively among the patients with EDTA≤120ml/min while the respective occurrences were 1.2%, 6.5% and 2.4% of cycles in patients with EDTA>120ml/min.

Discussion
This study has demonstrated excellent efficacy in metastatic seminoma using single agent carboplatin AUC10. The results are comparable with those using combination cisplatin based therapy but with more modest non - haematological toxicity. The use of PET - CT allowed the number of patients receiving 4 cycles to be reduced to 43% compared to the approach we had previously used using radiological CR after one cycle. This suggests that using PET - CT in this way was effective in sparing patients a final cycle of chemotherapy. However, we do not know whether the 4th cycle was needed at all. There was a significant association between the volume of disease prior to therapy and the chance of achieving a metabolic CR. A pragmatic argument can be made for using the volume of disease at the start and deciding on how many cycles a patient is going to have rather than relying on a PET - CT during therapy. This would mean simply giving all patients with stage 2A and 2B disease 3 cycles and those with greater disease 4 cycles. However, the association was not strong enough (rho=-0.48) to rely on simply volume of disease rather than PET - CT. Both patients who relapsed in this study and the patient who relapsed in our pilot study had received 4 cycles of carboplatin – suggesting that under-dosing in terms of cycles was not the cause of relapse.

The lack of acute toxicity within this study was striking – the fact that these results were achieved with a simple 1-hour infusion makes this therapy very patient friendly. Most patients had minimal delay between cycles and few required dose reductions during treatment (9 patients). There was no hair loss with this therapy.
Previous studies have demonstrated good outcome with lower doses of carboplatin but with the addition of other agents (e.g. cyclophosphamide) – this is likely to be less attractive because haematological toxicity is still significant with many patients requiring platelet transfusions and the increased risk of infertility.

Metastatic seminoma is becoming more frequent. Stage 1 disease is increasingly managed by surveillance. Adjuvant therapy in the stage 1 setting reduces risk of recurrence, although some have claimed that single agent carboplatin in this setting is not effective enough for it to become standard of care.

The use of radiotherapy in this setting is associated with second cancers. Surveillance for stage 1 disease means that there will be more recurrences requiring therapy. For stage 2A/B disease the low volume mean's high cure rates can be obtained using radiotherapy or induction chemotherapy followed by radiotherapy, – both present problems in terms of the risk of secondary malignancies – a situation analogous to Hodgkin’s lymphoma. For more advanced disease (2C and above) combination chemotherapy is usually used.

To date carboplatin at least in the adjuvant setting has not been associated with secondary malignancies or raised cardiovascular risk – unlike the situation with combination cisplatin based therapies. A majority of patients failing single agent chemotherapy can be salvaged with combination chemotherapy (most frequently BEP).

This study has shown that haematological toxicity remains a weakness for this approach, however, a stricter transfusion policy – limiting red cell transfusion to patients with haemoglobin less than 70g/l, would probably reduce this further. Some treatment delays were due to slow recovery of neutrophil counts - again as so few episodes of neutropenia were accompanied by fever – reducing the lower limit to proceeding with the treatment to $0.5 \times 10^9/l$ would probably reduce delays.

The range of renal function in this study was quite broad there was no suggestion that patients with uncorrected (for surface area) renal function with GFR> 120ml/min were more likely to develop low blood counts. This confirms the validity of using uncorrected GFR when using the Calvert formula and no cap on total carboplatin dosage should be used.

This study has obvious shortcomings - it is a single arm phase 2 study limiting the confidence we can have that the results would not have been better with combination chemotherapy. The
ototoxicity recorded was symptomatic – formal audiograms were not carried out and it is clear that carboplatin at this dose is not free from ototoxicity. The absence of formal audiograms is clearly a weakness of this study. We cannot directly comment on long-term toxicity.

In conclusion, carboplatin monotherapy is an effective for metastatic seminoma, the convenience and low number of acute side effects make it worthy of consideration in the management of metastatic good prognosis seminoma. PET scanning after 1 cycle may allow a reduction in therapy but the case for this has not been proven.

**Additional information**

*Ethics approval and consent to participate*

Ethics approval for the study was obtained from the London - City & East Research Ethics Committee. All patients provided written informed consent prior to participation in the study. The study was performed in accordance with the declaration of Helsinki.

*Consent for publication*

The manuscript does not include any personal data.

*Availability of data and material*

Data is held centrally by the Centre for Experimental Cancer Medicine, Queen Mary University of London.

*Funding*

The study was supported by the Orchid Charity.

*Authors’ contributions*

JS was the Chief Investigator of the study.

CC coordinated operational aspects of the study.

JS, RS, NS, AS, KM and GR were involved in recruitment, clinical care, and data returns.

RS performed central review of PET scans for the study.

PW provided statistical support for the study.
SJS was the study statistician and performed the main analysis for the study.

JS and SJS compiled the manuscript with input and support from RS, NS, AS, KM, CC, PW and GR.

Acknowledgements

The study was sponsored by Barts Health NHS Trust and supported by the Orchid Charity who provided a grant towards trial management including clinical trial nurse support. We thank all participating patients and the CRUK Experimental Cancer Medicine Centre for support.

Conflict of Interest Statement

The authors declare no conflicts of interest.
References


### Tables and Figures

#### Table 1 Deauville Criteria

<table>
<thead>
<tr>
<th>Degree of Glucose uptake</th>
<th>Deauville criteria</th>
<th>Metabolic response</th>
</tr>
</thead>
<tbody>
<tr>
<td>No uptake</td>
<td>1</td>
<td>complete</td>
</tr>
<tr>
<td>Equal to mediastinal blood pool</td>
<td>2</td>
<td>complete</td>
</tr>
<tr>
<td>Equal to the liver</td>
<td>3</td>
<td>Complete</td>
</tr>
<tr>
<td>Moderately increased &gt; liver</td>
<td>4</td>
<td>Partial</td>
</tr>
<tr>
<td>Markedly increased &gt; liver and/or new lesions</td>
<td>5</td>
<td>Progressive disease</td>
</tr>
</tbody>
</table>
Table 2 Patient Demographic and tumour characteristics at baseline

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Statistics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>48</td>
</tr>
<tr>
<td>Age in years: Median (range)</td>
<td>36 (24 – 66)</td>
</tr>
<tr>
<td>Primary Tumor</td>
<td></td>
</tr>
<tr>
<td>Testis</td>
<td>46</td>
</tr>
<tr>
<td>Mediastinum</td>
<td>1</td>
</tr>
<tr>
<td>Retroperitoneum</td>
<td>1</td>
</tr>
<tr>
<td>Sites of metastases</td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td>2</td>
</tr>
<tr>
<td>Lymph nodes</td>
<td>29</td>
</tr>
<tr>
<td>Other</td>
<td>9</td>
</tr>
<tr>
<td>ECOG PS</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>41</td>
</tr>
<tr>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>missing</td>
<td>5</td>
</tr>
<tr>
<td>Stage, number (%)</td>
<td></td>
</tr>
<tr>
<td>2A</td>
<td>13 (27%)</td>
</tr>
<tr>
<td>2B</td>
<td>23 (48%)</td>
</tr>
<tr>
<td>2C</td>
<td>11 (23%)</td>
</tr>
<tr>
<td>NA (Mediastinal)</td>
<td>1</td>
</tr>
<tr>
<td>Tumor markers</td>
<td></td>
</tr>
<tr>
<td>AFP: All normal</td>
<td></td>
</tr>
<tr>
<td>BHCG: Median (range)</td>
<td>1 (1-102)</td>
</tr>
<tr>
<td>normal (&lt;3)</td>
<td>36</td>
</tr>
<tr>
<td>Raised</td>
<td>12 (3-7: 8, 8-100: 3 and &gt;100:1)</td>
</tr>
<tr>
<td>LDH: Median (range)</td>
<td>406 (&lt;190-2657)</td>
</tr>
<tr>
<td>Normal (LDH&lt;ULN:480)</td>
<td>34 (71%)</td>
</tr>
<tr>
<td>Raised (LDH≥ULN &amp; LDH&lt;3xULN)</td>
<td>11 (23%)</td>
</tr>
<tr>
<td>Raised (LDH≥3xULN)</td>
<td>2 (4%)</td>
</tr>
<tr>
<td>Missing</td>
<td>1 (2%)</td>
</tr>
<tr>
<td>GFR: median (range)</td>
<td>106ml/min (68 - 236)</td>
</tr>
<tr>
<td>EDTA</td>
<td>43 (GFR&gt;120ml/min: 9)</td>
</tr>
<tr>
<td>Calculated clearance</td>
<td>05 (GFR&gt;120ml/min: 4)</td>
</tr>
</tbody>
</table>
Table 3: Association between disease stage and patient responses at the end of cycle 1 and the final radiological response at the end of treatment

<table>
<thead>
<tr>
<th>Metabolic response at cycle 1</th>
<th>Disease Stage</th>
<th></th>
<th></th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2A</td>
<td>2B</td>
<td>2C</td>
<td></td>
</tr>
<tr>
<td>CR</td>
<td>9</td>
<td>12</td>
<td>0</td>
<td>21</td>
</tr>
<tr>
<td>PR</td>
<td>4</td>
<td>11</td>
<td>11</td>
<td>26</td>
</tr>
<tr>
<td>Total</td>
<td>13</td>
<td>23</td>
<td>11</td>
<td>47</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Overall response</th>
<th>CR</th>
<th>PR-ve</th>
<th>SD-ve</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>11</td>
<td>2</td>
<td>0</td>
<td>32</td>
</tr>
<tr>
<td>PR-ve</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>SD-ve</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Total</td>
<td>13</td>
<td>22</td>
<td>11</td>
<td>46</td>
</tr>
</tbody>
</table>

Fisher’s exact test (between metabolic response and disease stage) $P=0.001$

Table 4: Grade 3/4 toxicities per cycle delivered and the number of patients affected

<table>
<thead>
<tr>
<th>Grade 3/4 Toxicity</th>
<th>Number of cycles - affected (%)</th>
<th>Number of patients by grade 3/4 toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutropenia</td>
<td>43 (25.6)</td>
<td>24</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>33 (19.6)</td>
<td>21</td>
</tr>
<tr>
<td>Anaemia</td>
<td>12 (7.1)</td>
<td>9</td>
</tr>
<tr>
<td>Fatigue</td>
<td>3 (1.8)</td>
<td>3</td>
</tr>
<tr>
<td>Febrile neutropenia</td>
<td>4 (2.4)</td>
<td>3</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3 (1.8)</td>
<td>3</td>
</tr>
<tr>
<td>Nausea</td>
<td>2 (1.2)</td>
<td>2</td>
</tr>
<tr>
<td>Mucositis (oral)</td>
<td>2 (1.2)</td>
<td>1</td>
</tr>
<tr>
<td>Pain</td>
<td>2 (1.2)</td>
<td>2</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>1 (0.6)</td>
<td>1</td>
</tr>
<tr>
<td>Headache</td>
<td>1 (0.6)</td>
<td>1</td>
</tr>
<tr>
<td>Insomnia</td>
<td>1 (0.6)</td>
<td>1</td>
</tr>
<tr>
<td>Tinnitus</td>
<td>1 (0.6)</td>
<td>1</td>
</tr>
<tr>
<td>GI toxicity bleed</td>
<td>1 (0.6)</td>
<td>1</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>109 (65%)</td>
<td></td>
</tr>
</tbody>
</table>

*Percentages are calculated based on total 168 cycles of treatment.
Figure 1: Treatment Flowchart

- **Baseline PET-CT**
- **Contrast enhanced CT scan** (Within 28 days of study entry)
  
  NB: If PET-CT was done instead of CT scan then the CT scan is not required if clinician already suspected diagnosis.

**Cycle 1**

**Day 17-21 PET-CT scan**
(With low attenuation CT)

**Partial Response**
Shown on Day 17-21 PET-CT scan

**Further 2 cycles**
(3 in total)

**Complete metabolic response**
on Day 17-21 PET-CT scan

**Further 3 cycles**
(4 in total)

**Contrast enhanced CT scan**
(Within 28 days of end of treatment)

**PET-CT scan**
(Within 28 days of end of treatment)

If Residual masses >3cm

**1 & 2 year post treatment contrast enhanced CT scan**

**Progression-Off Study**
Patient to receive conventional cisplatin therapy

**Yes**

**Contrast enhanced CT scan at 2-3 months post end of treatment scan**

**Yes**

**Contrast enhanced CT scan**
2-3 months post-surgery & again at 2 years
Figure 2: Blood count guide prior to treatment.

Day 1 of each cycle

Blood check

*Platelets >100 x10^9/L
WBC >3 x10^9/L or
*Neutrophils >1 x10^9/L

Yes

Recheck blood after 48 hours

*Platelets ≥ 75 x10^9/L
& rising
WBC >3 x10^9/L or
*Neutrophils >1 x10^9/L

No

Yes

Recheck blood after 48 hours

*Platelets ≥ 75 x10^9/L
& rising
WBC >3 x10^9/L or
*Neutrophils >1 x10^9/L

No

Yes

Study Treatment

No

Study Treatment

*If the patient has a nadir platelets count (day 13-17) of <20 x10^9/L the dose of carboplatin should be reduced by 20%.

*If the neutrophil count is < 1 x10^9/L and white blood count < 3 x10^9/L then GCSF should be given for 2 days.

Continue to recheck blood every 48 hours.

After 14 day delay patient off study.